 |
 |
|
|
RESÚMENES JULIO 2006 |
Psychotic Disorders & Antipsychotics
(Haga un click en la información del journal
para acceder al resúmen)
Ten-Year Recovery Outcomes for Clients With
Co-Occurring Schizophrenia and Substance Use Disorders
Robert E. Drake, Gregory J. McHugo, Haiyi Xie,
Melinda Fox, Joan Packard and Barbara Helmstetter
Schizophrenia
Bulletin 2006 32(3):464-473
Neuropsychological Functioning in
Adolescents and Young Adults at Genetic Risk for Schizophrenia and Affective
Psychoses: Results from the Harvard and
Larry J. Seidman, Anthony J. Giuliano, Christopher W. Smith,
William S. Stone, Stephen
J. Glatt, Eric Meyer, Stephen V. Faraone, Ming T. Tsuang and Barbara Cornbla
Schizophrenia
Bulletin 2006 32(3):507-524
Factors Mediating Cognitive Deficits and
Psychopathology Among Siblings of Individuals With Schizophrenia
Zainab Delawalla, Deanna M. Barch,
Jennifer L. Fisher Eastep, Emily S. Thomason, Melissa
J. Hanewinkel, Paul A. Thompson and John G. Csernansky
Schizophrenia
Bulletin 2006 32(3):525-537
Generalized and Specific Cognitive
Performance in Clinical High-Risk Cohorts: A Review Highlighting Potential
Vulnerability Markers for Psychosis
Warrick J. Brewer, Stephen J.
Wood, Lisa J. Phillips, Shona M. Francey,
Christos Pantelis, Alison R. Yung, Barbara Cornblatt and Patrick D. McGorry
Schizophrenia
Bulletin 2006 32(3):538-555
Therapeutic Effects of Individualized Alpha
Frequency Transcranial Magnetic Stimulation (
TMS)
on the Negative Symptoms of Schizophrenia
Yi Jin, Steven G. Potkin, Aaron S. Kemp, Steven T. Huerta, Gustavo Alva, Trung Minh Thai, Danilo Carreon and William E. Bunney,
Jr.
Schizophrenia
Bulletin 2006 32(3):556-561
The Presence of Neurological Soft Signs
Along the Psychosis Proneness Continuum
Emma Barkus,
John Stirling, Richard Hopkins and Shôn Lewis
Schizophrenia
Bulletin 2006 32(3):573-577
Health Status of Individuals With Serious
Mental Illness
Faith B. Dickerson, Clayton H.
Brown, Gail L. Daumit, Fang LiJuan,
Richard W. Goldberg, Karen Wohlheiter and Lisa B.
Dixon
Schizophrenia
Bulletin 2006 32(3):584-589
Patterns of, and factors associated with, atypical
and typical antipsychotic prescribing by general practitioners in the
Derek
King and Martin Knapp
Journal
of Mental Health. Volume 15, Number 3 / June 2006: 269 - 278
High-dose
of multiple antipsychotics and cognitive function in
schizophrenia: The effect of dose-reduction
Nobutoshi Kawai, Yuriko Yamakawa,
Atsuomi Baba, Kiyotaka Nemoto, Hirokazu Tachikawa Takafumi Hori, Takashi
Asada and Tetsuya Iidaka
Switching
to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: An open
trial
Hitoshi Takahashi, Keizo
Yoshida, Jun Ishigooka and Hisashi
Higuchi
The
effect of perospirone on auditory P300 in
schizophrenia: A preliminary study
Tsuyoshi Araki, Kiyoto Kasai, Mark A. Rogers, Nobumasa Kato and Akira Iwanami
Cigarette
smoking in long-term schizophrenia
R.K.R. Salokangas, T. Honkonen, E. Stengård, A.-M. Koivisto and J. Hietala
European Psychiatry. Volume 21, Issue 4, June 2006, Pages 219-223
Oral
glucose tolerance tests in treated patients with schizophrenia. Data to support
an adaptation of the proposed guidelines for monitoring of patients on second
generation antipsychotics?
Marc De Hert, Dominique
Van Eyck, Linda Hanssens, Hendrik
Peuskens, Erik Thys, Martien Wampers, Andre Scheen and Jozef Peuskens
European Psychiatry. Volume 21, Issue 4, June
2006, Pages 224-226
Social
class and type of schizophrenia
B.J. Gallagher III, B.J. Jones, J.A. McFalls, Jr. and A.M. Pisa
European
Psychiatry. Volume
21, Issue 4, June 2006, Pages 233-237
A
survey of general practitioners’ knowledge of symptoms and epidemiology of
schizophrenia
Hélène Verdoux, Audrey Cougnard, Sabrina Grolleau,
Rachel Besson and Françoise Delcroix
European
Psychiatry. Volume
21, Issue 4, June 2006, Pages 238-244
Differentiation
of adoptees at high versus low genetic risk
for schizophrenia by adjusted MMPI indices
Virva Siira, Karl-Erik
Wahlberg, Jouko Miettunen, Pekka Tienari and Kristian Làksy
European
Psychiatry. Volume
21, Issue 4, June 2006, Pages 245-250
Effects of atypical and typical antipsychotic
treatments on sexual function in patients with schizophrenia:
12-month results from the Intercontinental Schizophrenia Outpatient Health
Outcomes (IC-SOHO) study
Martin Dossenbach, Yulia Dyachkova, Sebnem
Pirildar, Martin Anders, Afaf Khalil, Aleksander Araszkiewicz, Tamara
Shakhnovich, Aly Akram, Jan Pecenak, Margaret McBridei and Tamas Treuer
European
Psychiatry. Volume
21, Issue 4, June 2006, Pages 251-258
Intramuscular
Ziprasidone Treatment of Acute Psychotic Agitation in Elderly Patients With
Schizophrenia
Yoram Barak,
Doron Mazeh, Igor Plopski, and Yehuda Baruch
Am J
Geriatr Psychiatry 14:629-633, July 2006
Heritability of schizophrenia and
major affective disorder as a function of age, in the presence of strong cohort
effects
J. Husted,
C. M. T. Greenwood and A. S. Bassett
European
Archives of Psychiatry and Clinical Neuroscience 2006; Volume 256, Number
4: 222 - 229
Identification of young people at risk of
psychosis
Sophie Parker and Shôn Lewis
Advances in Psychiatric Treatment (2006) 12: 249-255
Initial treatment phase in early psychosis:
can intensive home treatment prevent admission?
Matthew Gould, Kate Theodore,
Stephen Pilling, Paul Bebbington, Mark Hinton, Sonia
Johnson
Psychiatric Bulletin (2006)
30: 243-246
Violence, stigma and psychiatric diagnosis:
the effects of a history of violence on psychiatric diagnosis
Tom Clark,
Renarta Rowe
Psychiatric
Bulletin (2006) 30: 254-256
Prevalence of the Metabolic Syndrome Among
Patients Receiving Clozapine
J. Steven Lamberti,
David Olson, John F. Crilly, Telva
Olivares, Geoffrey C. Williams, Xin Tu, Wan Tang, Karen Wiener, Steven Dvorin,
and Marci B. Dietz
American
Journal of Psychiatry 163:1273-1276, July 2006
Association of Initial Antipsychotic
Response to Clozapine and Long-Term Weight Gain
Ya Mei Bai, Chao-Cheng Lin, Jen-Yeu Chen, Chih-Yuan Lin,
Tung-Ping Su, and Pesus Chou
American
Journal of Psychiatry 163:1276-1279, July 2006
Predictors of Tobacco Use Among Persons With
Mental Illnesses in a Statewide Population
Chad D. Morris, Alexis A. Giese,
Jennifer J. Turnbull, Miriam Dickinson, and Nancy Johnson-Nagel
Psychiatr
Serv 57:1035-1038, July 2006
Premorbid
functioning and treatment response in recent-onset schizophrenia
Jonathan Rabinowitz,
Philip D. Harvey, Marielle Eerdekens,
Michael Davidson
The British Journal of Psychiatry (2006) 189: 31-35
Dose Decrease and Other Correlates of Relapse in
Patients with Schizophrenia or Schizoaffective Disorder During Olanzapine Drug Therapy
W. Deberdt,
J. Csernansky, P. Buckley, J. Peiskens, I. Lipkovich,
S. Kollack-Walter, J. Houston,
Y. Zhang, H. Liu-Siefert
NeuroRx. Volume 3, Issue 3, Page 409 (July 2006)
Three
dimensions of clinical symptoms in elderly patients with schizophrenia:
Prediction of six-year cognitive and functional status
Eran Chemerinski,
Abraham Reichenberg, Brian Kirkpatrick, Christopher
R. Bowie and Philip D. Harvey
Schizophrenia
Research. Volume
85, Issues 1-3, July 2006, Pages 12-19
A
double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia
experiencing an acute exacerbation requiring hospitalization
Steven G. Potkin, Georges
M. Gharabawi, Andrew J. Greenspan, Ramy Mahmoud, Colette Kosik-Gonzalez, Marcia F.T. Rupnow,
Cynthia A. Bossie, Michael Davidson, Victoria Burtea, Young Zhu and Jintendra
K. Trivedi
Schizophrenia
Research. Volume
85, Issues 1-3, July 2006, Pages 254-265
Cognitive
effects of adjunctive 24-weeks Rivastigmine treatment
to antipsychotics in schizophrenia: A randomized,
placebo-controlled, double-blind investigation
Tonmoy Sharma, Catherine
Reed, Ingrid Aasen and Veena
Kumari
Schizophrenia
Research. Volume
85, Issues 1-3, July 2006, Pages 73-83
Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome
Joanna L. Rosen, Tandy J. Miller, Jennifer T. D'Andrea, Thomas H. McGlashan and
Scott W. Woods
Schizophrenia
Research. Volume
85, Issues 1-3, July 2006, Pages 124-131
Impact
of haloperidol, a dopamine D2 antagonist, on cognition and mood
Huma Saeedi,
Gary Remington and Bruce K. Christensen
Schizophrenia Research. Volume 85, Issues 1-3, July 2006, Pages 222-231
Modifiable risk factors for
hospitalization among people with psychosis: evidence from the National Study
of Low Prevalence (Psychotic) Disorders
Vera
Morgan, Ailsa Korten, Assen Jablensky
Australian and New Zealand Journal of Psychiatry. Volume 40 Page
683 - August 2006
Effect of omega-3 fatty
acids on the lipid profile of patients taking clozapine
Riccardo
N. Caniato, Marlies E. Alvarenga, Miguel Angel Garcia-Alcaraz
Australian and New Zealand
Journal of Psychiatry. Volume 40 Page 691 -
August 2006
Evaluation of factors influencing medication
compliance in inpatient treatment of psychotic disorders
Birgit Janssen,
Wolfgang Gaebel, Martin Haerter,
F. Komaharadi, Birgit Lindel
and Stefan Weinmann
Psychopharmacology
2006; Volume 187, Number 2: 229 - 236
Total antioxidant response in patients with
schizophrenia
BILAL USTUNDAG, MURAD
ATMACA, OZLEM KIRTAS, SAHABETTIN SELEK, KEREM METIN, AND ERTAN TEZCAN
Psychiatry and Clinical
Neurosciences. Volume 60 Page 458 - August 2006
Cognitive function and social abilities in patients
with schizophrenia: Relationship with atypical antipsychotics
PHILIP J. TYSON, KEITH
R. LAWS, KENNETH A. FLOWERS, AGI TYSON, AND ANN M. MORTIMER
Psychiatry and Clinical
Neurosciences. Volume 60 Page 473 - August 2006
Adjusting the frequency of continuation and
maintenance electroconvulsive therapy to prevent relapse of catatonic
schizophrenia in middle-aged and elderly patients who are relapse-prone
KAZUMASA SUZUKI, SHUICHI
AWATA, TAKEHISA TAKANO, YUKIO EBINA, TSUYOSHI SHINDO, NOBUHIKO HARADA, AND
HIROO MATSUOKA
Psychiatry and Clinical
Neurosciences. Volume 60 Page 486 - August 2006
Increase in schizophrenia incidence rates: findings
in a Canadian cohort born 1975–1985
Isabelle Bray,
Paul Waraich, Wayne Jones,
Serena Slater, Elliot M. Goldner and
Julian Somers
Social
Psychiatry and Psychiatric Epidemiology 2006; Volume 41, Number 8: 611 - 618
Characterization
of the serotonin transporter in lymphocytes and platelets of schizophrenia
patients treated with atypical or typical antipsychotics
compared to healthy individuals
Tal Barkan, Avi Peled, Ilan
Modai, Abraham Weizman and
Moshe Rehavi
European Neuropsychopharmacology.
Volume 16,
Issue 6, August 2006, Pages 429-436
Diminished
neurocardiac dynamics associated with
antipsychotic-induced extrapyramidal syndrome
Jong-Hoon Kim, Sang Hoon Yi, Kyung Tae Park, Yong Min Ahn,
Kyu Young Lee, Seung Ae Yang and Yong Sik Kim
European Neuropsychopharmacology.
Volume 16,
Issue 6, August 2006, Pages 459-463
Tardive Dyskinesia in Schizophrenia is
Associated with Prolactin-Related Sexual Disturbances
Diederik E Tenback,
Peter N van Harten, Cees
J Slooff and Jim van Os the SOHO Study
Group
Neuropsychopharmacology (2006) 31,
1832–1837
Association Between Attitude Toward Medication and Neurocognitive Function in Schizophrenia
Kim,
Sung-Wan; Shin, Il-Seon; Kim, Jae-Min; Yang, Su-Jin;
Shin, Hee-Young; Yoon, Jin-Sang
Clinical Neuropharmacology. 29(4):197-205, July/August 2006
Hospitalization Risks in the Treatment of
Schizophrenia: Comparison of Antipsychotic Medications
Gianfrancesco, Frank; Rajagopalan, Krithika;
Wang, Ruey-hua
Journal of Clinical Psychopharmacology. 26(4):401-404,
August 2006
Cross-sectional Comparison of Fasting Lipids in Normoglycemic Patients With Schizophrenia During Chronic
Treatment With Olanzapine, Risperidone,
or Typical Antipsychotics
Hardy,
Thomas A.; Marquez, Eva; Kryzhanovskaya, Ludmila; Taylor, Cindy C.; Cavazzoni,
Patrizia
Journal of Clinical Psychopharmacology. 26(4):405-408,
August 2006
Bupropion
Treatment of Olanzapine-Associated Weight Gain: An
Open-Label, Prospective Trial
Gadde, Kishore M.; Zhang, Wei; Foust, Mariko S
Journal of Clinical Psychopharmacology. 26(4):409-413,
August 2006
Evaluation of an Interchangeability Switch
in Patients Treated With Clozapine: A Retrospective
Review
Silvia Alessi-Severini, Patricia L. Honcharik,
Karleen D. Simpson, Michael K. Eleff,
and David M. Collins
J Clin Psychiatry
2006;67:1047-1054
Comparison of Quetiapine
and Risperidone in the Treatment of Schizophrenia: A
Randomized, Double-Blind, Flexible-Dose, 8-Week Study
Kate X. Zhong, Dennis E. Sweitzer, Robert M. Hamer, and Jeffrey A.
Lieberman
J Clin Psychiatry
2006;67:1093-1103
A Prospective Study of Risk Factors for Nonadherence With Antipsychotic Medication in the Treatment
of Schizophrenia
Haya Ascher-Svanum,
Baojin Zhu, Douglas Faries,
Jonathan P. Lacro, and Christian R. Dolder.
J Clin Psychiatry
2006;67:1114-1123
The neurocognitive
effects of aripiprazole: an open-label comparison
with olanzapine
Robert S. Kern,
Michael F. Green, Barbara A. Cornblatt,
J. Randall Owen, Robert D. McQuade,
William H. Carson, Mirza Ali and
Ron Marcus
Psychopharmacology 2006; Volume 187, Number 3: 312 - 320
Neurological
soft signs in adolescents with first episode psychosis
Arantzazu Zabala, Olalla Robles, Mara Parellada,
Dolores Maria Moreno, Ana Ruiz-Sancho, Maite Burdalo, Oscar Medina and Celso Arango
European
Psychiatry. Volume
21, Issue 5, July 2006, Pages 283-287
Dropout rates in placebo-controlled and
active-control clinical trials of antipsychotic drugs—a meta-analysis
Kemmler G, Hummer M, Widschwendter C, et al.
Arch Gen Psychiatry
2005;62:1305–12
One-year double-blind study of the neurocognitive efficacy of olanzapine,
risperidone, and haloperidol in schizophrenia
Keefe
RSE, Young CA, Rock SL, et al.
Course and predictors of weight gain in
people with first-episode psychosis treated with olanzapine
or haloperidol
Zipursky RB, Gu HB, Green AI, et
al.
Br J Psychiatry
2005;187:537–43
Baseline Use of Concomitant Psychotropic
Medications to Treat Schizophrenia in the CATIE Trial
Miranda H.
Chakos, Ira D. Glick, Alexander L. Miller, Mark B. Hamner, Del D. Miller,
Jayendra K. Patel, Andre Tapp, Richard S. E. Keefe, and Robert A. Rosenheck
Psychiatr
Serv 57:1094-1101, August 2006
Interrelationships of Psychiatric Symptom
Severity, Medical Comorbidity, and Functioning in
Schizophrenia
Lydia A. Chwastiak,
Robert A. Rosenheck, Joseph P. McEvoy,
Richard S. Keefe, Marvin S. Swartz, and Jeffrey A. Lieberman
Psychiatr
Serv 57:1102-1109, August 2006
Substance Use and Psychosocial Functioning
in Schizophrenia Among New Enrollees in the NIMH CATIE Study
Marvin S. Swartz, H. Ryan Wagner,
Jeffrey W. Swanson, T. Scott Stroup, Joseph P. McEvoy,
Mark McGee, Del D. Miller, Fred Reimherr, Ahsan Khan, José M. Cañive, and
Jeffrey A. Lieberman
Psychiatr
Serv 57:1110-1116, August 2006
Treatment of Cardiac Risk Factors Among
Patients With Schizophrenia and Diabetes
Anthony P. Weiss, David C.
Henderson, Jeffrey B. Weilburg, Donald C. Goff, James
B. Meigs, Enrico Cagliero, and Richard W. Grant
Psychiatr Serv
57:1145-1152, August 2006
Schizophrenia and violence: a search for
neurobiological correlates
Naudts,
Kris; Hodgins, Sheilagh
Current
Opinion in Psychiatry. 19(5):533-538, September 2006
Pyridoxine
for drug induced dyskinesia: A placebo-controlled
randomized cross-over trial
VENEGAS F, Pablo, SINNING O, Mariana, MILLAN A, María et al
Rev. chil. neuro-psiquiatr., Mar. 2006, vol.44, no.1,
p.9-14